Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis

医学 任天堂 吡非尼酮 耐受性 中止 内科学 特发性肺纤维化 肺活量 回顾性队列研究 胃肠病学 外科 不利影响 肺 扩散能力 肺功能
作者
William Alexander Wright,Louise Crowley,Dhruv Parekh,Anjali Crawshaw,Davinder Dosanjh,Peter Nightingale,David Thickett
出处
期刊:BMJ Open Respiratory Research [BMJ]
卷期号:8 (1): e000782-e000782 被引量:22
标识
DOI:10.1136/bmjresp-2020-000782
摘要

Background Pirfenidone and nintedanib are the only disease-modifying treatments available for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in clinical practice. Methods This is a single-centre retrospective observational study undertaken at a specialised interstitial lung disease centre in England. Data including progression-free survival (PFS), mortality and drug tolerability were compared between patients with IPF on antifibrotic therapies and an untreated control group who had a forced vital capacity percentage (FVC %) predicted within the licensed antifibrotic treatment range. Results 104 patients received antifibrotic therapies and 64 control patients were identified. PFS at 6 months was significantly greater in the antifibrotic group (75.0%) compared with the control group (56.3%) (p=0.012). PFS was not significant at 12 or 18 months when comparing the antifibrotic group with the control group. The 12-month post-treatment mean decline in FVC % predicted (−4.6±6.2%) was significantly less than the 12-month pretreatment decline (−10.4±11.8%) (p=0.039). The 12-month mortality rate was not significantly different between the antifibrotic group (25.3%) and the control group (35.5%) (p=0.132). Baseline Body Mass Index of≤25, baseline diffusion capacity for carbon monoxide percentage predicted of ≤35 and antifibrotic discontinuation within 3 months were independent predictors of 12-month mortality. Antifibrotic discontinuation was significantly higher by 3 and 6 months for patients on pirfenidone than those on nintedanib (p=0.006 and p=0.044, respectively). Discontinuation at 12 months was not significantly different (p=0.381). Conclusions This real-world study revealed that antifibrotics are having promising effects on PFS, lung function and mortality. These findings may favour commencement of nintedanib as first-line antifibrotic therapy, given the lower rates of early treatment discontinuation, although further studies are required to investigate this.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
sunnymoon发布了新的文献求助10
1秒前
犹豫的若发布了新的文献求助10
1秒前
小周发布了新的文献求助10
1秒前
丰富的德天完成签到 ,获得积分10
2秒前
2秒前
3秒前
3秒前
3秒前
3秒前
qingsan完成签到,获得积分10
3秒前
JJ发布了新的文献求助10
4秒前
41发布了新的文献求助10
4秒前
4秒前
FashionBoy的应助被科研通管家采纳,获得10
4秒前
null的应助被科研通管家采纳,获得10
4秒前
旧是完成签到 ,获得积分10
4秒前
玛卡巴卡的应助被科研通管家采纳,获得100
4秒前
李健的应助被科研通管家采纳,获得10
4秒前
时觉觉发布了新的文献求助10
4秒前
脑洞疼的应助被科研通管家采纳,获得10
5秒前
wanci的应助被科研通管家采纳,获得10
5秒前
yyyyy发布了新的文献求助10
5秒前
5秒前
5秒前
null的应助被科研通管家采纳,获得10
5秒前
5秒前
ppp完成签到,获得积分10
5秒前
Maestro_S的应助被科研通管家采纳,获得10
5秒前
6秒前
深情安青的应助被科研通管家采纳,获得10
6秒前
川了秋依关注了科研通微信公众号
6秒前
6秒前
6秒前
热心市民小红花的应助被赵赵a采纳,获得10
6秒前
7秒前
菠菜发布了新的文献求助30
7秒前
呐呐呐发布了新的文献求助10
7秒前
7秒前
luluyuan2010完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161554
求助须知:如何正确求助?哪些是违规求助? 9556174
关于积分的说明 21732775
捐赠科研通 7751537
什么是DOI,文献DOI怎么找? 3427556
关于科研通互助平台的介绍 2552588
邀请新用户注册赠送积分活动 2472023